The company opened a new facility in Dublin for its cell performance technology.
On Nov. 30, 2016 Valitacell opened a new facility at the National Institute for Bioprocessing Research and Training (NIBRT) in Dublin, Ireland. The team will include a staff of four led by Terry McWade, CEO. Valitacell is an Irish early-stage life-science company with technologies that improve cell performance. Valitacell’s ChemStress technology replicates the stress cells encounter in an industrial bioreactor. This is achieved by coating the wells of the 96-well plastic plate with chemicals that have been selected based on their ability to impact the cells’ metabolism.
Chinese hamster ovary (CHO) cells are grown on the plate, and the response of the cells to the individual chemicals is measured in terms of cell growth and ability to produce the drug. The overall response to the individual chemicals is known as the stress response fingerprint. The stress response fingerprint is the basis for several applications that when combined with analytical algorithms, can predict cell performance, cell stability, confirm cell identity, and detect batch-to-batch changes in the food media used to grow the cells. The initial target for Valitacell’s technology is the biologic drug market.
Source: Valitacell
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.